DOVA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-0.07% | +269.92% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Dova Pharmaceutic...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Companyâs initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Companyâs product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| +269.92% | 808M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +3.76% | 22.25B | |
| -14.77% | 21.68B | |
| -8.63% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- DOVA Stock
- News Dova Pharmaceuticals, Inc.
- Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
